Express News | First Wave Biopharma Announced Research Generated From Two Previously Completed Phase 2 Clinical Trials Of Latiglutenase Has Been Published In The Special Issue In The Peer-reviewed Scientific Journal
Moomoo 24/7Apr 24 07:14 ET
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
BOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
GlobeNewswireApr 24 07:00 ET
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
GlobeNewswireApr 17 07:00 ET
Express News | HC Wainwright & Co. Reinstates Neutral on First Wave BioPharma
Moomoo 24/7Mar 25 06:44 ET
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
Poster presentations to highlight new quantitative and serologic diagnostic methods for Celiac Disease detection and determination of intestinal mucosal health New tools may serve as companion diagnostics for
GlobeNewswireMar 18 07:00 ET
First Wave BioPharma Is Maintained at Buy by Roth MKM
First Wave BioPharma Is Maintained at Buy by Roth MKM
Dow JonesMar 15 10:00 ET
Express News | Roth MKM Maintains Buy on First Wave BioPharma, Lowers Price Target to $36
Moomoo 24/7Mar 15 09:49 ET
First Wave BioPharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 627.27% Roth MKM $40 → $36 Maintains Buy 01/03/2024 708.08% Roth MKM $11 → $40 Maintains Buy 09
BenzingaMar 15 09:47 ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersBetter Therapeutics (NASDAQ:BTTX) shares increased by 85.4% to $0.06 during Friday's pre-market session. The market value of their outstanding shares is at $3.5 million. Madrigal Pharmaceutical
BenzingaMar 15 09:06 ET
Sector Update: Health Care Stocks Retreating Late Afternoon
Health care stocks fell late Thursday afternoon with the NYSE Health Care Index shedding 0.7% and the Health Care Select Sector SPDR Fund (XLV) down 0.4%. The iShares Biotechnology ETF (IBB) declined
MT NewswiresMar 14 15:56 ET
Sector Update: Health Care
Health care stocks were slipping late Thursday afternoon, with the NYSE Health Care Index shedding 0.5% and the Health Care Select Sector SPDR Fund (XLV) down 0.9%. The iShares Biotechnology ETF (IBB)
MT NewswiresMar 14 15:39 ET
Express News | First Wave BioPharma Shares Are Trading Lower After the Company Announced That It Completed Its Merger Deal With ImmunogenX
Moomoo 24/7Mar 14 13:05 ET
WIMI, FWBI and BMR Among Mid-day Movers
Seeking AlphaMar 14 13:02 ET
First Wave BioPharma Acquires ImmunogenX to Bolster GI Pipeline
InvestingMar 14 06:20 ET
First Wave BioPharma Completes Merger Deal With ImmunogenX Adding Phase 3-Ready Candidate For Celiac Disease
First Wave BioPharma Inc (NASDAQ:FWBI) has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a gastrointestinal (GI) pipeline.First Wave BioPharma signed a
BenzingaMar 14 06:00 ET
Press Release: First Wave BioPharma Announces Completion of Business Combination With ImmunogenX, Adding Phase 3-Ready Latiglutenase to Its Late-Stage GI-Focused Clinical Pipeline
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline Latiglutenase is a potentially fir
Dow JonesMar 14 06:00 ET
First Wave BioPharma to Participate In 'Fireside Chat' at the 36th Annual Roth Conference
BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
GlobeNewswireMar 5 07:00 ET
Express News | First Wave BioPharma Shares Are Trading Lower After the Company Announced a $4 Million Registered Direct Offering of 526,625 Shares at $7.61 per Share
Moomoo 24/7Mar 4 15:26 ET
JAGX, BBAI and BNTC Among Mid-day Movers
Seeking AlphaMar 4 12:35 ET
First Wave BioPharma Shares Drop 25% After Direct Offering Prices
By Chris Wack First Wave BioPharma shares were down 25% to $6.98 in premarket trading after the company entered into a definitive securities purchase agreement with a certain institutional investor f
WSJMar 4 08:42 ET
No Data
No Data